News
Brains Way Presents Positive Data from Largest Real-World Study of Deep TMS" in Patients with Comorbid PTSD and Major Depressive Disorder | Markets Insider
5+ hour, 14+ min ago (527+ words) Brains Way Presents Positive Data from Largest Real-World Study of Deep TMS" in Patients with Comorbid PTSD and Major Depressive Disorder markets. businessinsider. com Brains Way Presents Positive Data from Largest Real-World Study of Deep TMS" in Patients with Comorbid…...
Greenhouse Treatment Center Bolsters Behavioral Health Team with Two Experienced Psychiatric Nurse Practitioners
1+ mon, 4+ week ago (564+ words) Both practitioners will work directly with clients across the continuum of care, supporting psychiatric evaluations, medication management, and individualized treatment planning. Their extensive. .. Greenhouse Treatment Center Bolsters Behavioral Health Team with Two Experienced Psychiatric Nurse Practitioners GRAND PRAIRIE, Texas, April…...
ACTG Launches Landmark Study Evaluating Treatments for Depressive Disorders with or without Mild Neurocognitive Disorder among People Living with HIV
2+ mon, 4+ day ago (602+ words) Depressive disorders and MND both affect a significant portion of people living with HIV in the United States and worldwide, even when their HIV is successfully managed and treated with antiretroviral. .. ACTG Launches Landmark Study Evaluating Treatments for Depressive Disorders…...
BD" Releases Largest Multi'Modal Psychiatric Dataset to Accelerate Breakthroughs in Bipolar Disorder
2+ mon, 4+ week ago (365+ words) Washington, D. C. , March 30, 2026 (GLOBE NEWSWIRE) -- BD: Breakthrough Discoveries for thriving with Bipolar Disorder today announced the first public release of data from the BD Integrated Network Longitudinal Cohort Study (LCS). This marks the launch of the largest integrated dataset in the…...
Breakthrough Study Shows Cognitive Training Improves Resilience for Warfighters
5+ mon, 2+ week ago (620+ words) SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Results from the Warfighter Brain Fitness Study, which recently published in the journal Military Medicine, show that the combination of two brain. .. Breakthrough Study Shows Cognitive Training Improves Resilience for Warfighters SAN FRANCISCO, Jan. 12, 2026 (GLOBE…...
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative. ..
8+ mon, 3+ week ago (807+ words) NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (LB Pharmaceuticals" or the Company") (Nasdaq: LBRX) today announced that three posters featuring new and previously reported analyses from its Phase 2 NOVA1 clinical trial of LB-102 in acute schizophrenia will be presented at…...
Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting
5+ mon, 1+ week ago (426+ words) -- Met Primary Endpoint with 30mg Dose of RE104 with 23. 0-Point Total Score Reduction in Montgomery-sberg Depression Rating Scale (MADRS) on Day 7 (p=0. 0094) -- -- Demonstrated Rapid and Durable. .. Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum…...
Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
4+ mon, 1+ week ago (220+ words) This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. Although Helus Pharma is not advancing intravenous SPL026 in its…...
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
7+ mon, 2+ week ago (185+ words) Title: Brilaroxazine treatment effects on BDNF and inflammatory cytokines in schizophrenia: RECOVER trial in acute and stable patients over 1 year Session Name: A. 10. Schizophrenia Session Number: .. . Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label…...
HOPE Therapeutics, Inc. , an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
7+ mon, 2+ week ago (864+ words) HOPE Therapeutics, Inc. , an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health - ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using…...